The Evolution of Methadone Prescribing Practices

The opioid crisis in North America, driven by the increasing potency of unregulated drugs like fentanyl, has necessitated significant changes in the treatment of opioid use disorder (OUD). In Ontario, Canada, methadone treatment trends have adapted to address the heightened opioid tolerance among individuals. A comprehensive study conducted between January 2015 and July 2023 examined 73,633 methadone initiations among 35,309 unique individuals, revealing shifts in prescribing practices. These changes include higher starting doses and the adoption of combination therapy with slow-release oral morphine (SROM), reflecting efforts to meet the needs of those affected by the volatile unregulated drug supply.

Key Findings in Methadone Treatment Trends

Shift to Higher Starting Doses

One of the most notable methadone treatment trends is the move towards initiating treatment at higher doses. Prior to 2018, most methadone initiations (60.8% to 72.6%) started at doses below 30 mg. However, from 2018 onwards, a significant shift occurred, with 63.4% of initiations by July 2023 starting at 30 to less than 40 mg, compared to only 28.2% in January 2015. This change aligns with updated prescribing guidance introduced in 2020, which recommended starting methadone at 30 mg to better manage the increased opioid tolerance seen in individuals using fentanyl. The guidance also led to a four-fold increase in initiations at 40 to less than 50 mg by 2023, highlighting a response to evolving clinical needs.

Rise of Combination Therapy

Another critical trend is the increased use of combination therapy, where methadone is prescribed alongside SROM. Before September 2020, combination therapy was rare, with fewer than six episodes recorded. However, following the release of new prescribing recommendations at the 2020 Mentoring, Education, and Clinical Tools for Addiction–Partners in Health Integration (META-PHI) conference, combination therapy initiations rose steadily, reaching 1.6 episodes per 100,000 population by January 2023. This shift was accompanied by a decline in monotherapy initiations, indicating a move towards more flexible treatment approaches to address the complexities of OUD in the context of a fentanyl-dominated drug supply.

Limited Dose Titration: A Missed Opportunity

Despite progress in initiating methadone at higher doses, the study identified a significant challenge in methadone prescribing practices: limited dose titration in the first two weeks of treatment. Among monotherapy episodes initiated after September 2020, only 37.5% received a dose increase within six days, and 45.7% had no dose increase at all within the first two weeks. For combination therapy, the figures were even lower, with only 29.2% receiving a dose increase within six days and 51.5% seeing no increase. This lack of rapid dose titration represents a missed opportunity to achieve therapeutic doses quickly, which is crucial for managing cravings and withdrawal symptoms in individuals with high opioid tolerance. The META-PHI guidance recommends dose increases of 10 to 15 mg every three to five days, potentially reaching up to 45 mg within two weeks, yet many patients remain on subtherapeutic doses, risking treatment dissatisfaction and discontinuation.

Implications for Treatment and Recovery

These methadone treatment trends highlight the need for ongoing adaptation in OUD treatment. The shift towards higher starting doses and combination therapy reflects an understanding of the increased potency of unregulated drugs and the resulting opioid tolerance. However, the limited use of rapid dose titration suggests barriers, such as prescriber caution due to safety concerns or logistical issues like the need for in-person visits. Addressing these barriers is essential to ensure individuals receive effective treatment that supports long-term recovery. The study also underscores the importance of tailoring treatment to individual needs, as the fentanyl-driven crisis has made traditional low-dose, slow-titration approaches less effective.

The Broader Context of the Opioid Crisis

The opioid crisis, which has claimed over 500,000 lives in North America since 2016, is driven by the dominance of fentanyl in the unregulated drug supply, contributing to over 80% of opioid-related deaths since 2018. In Ontario, individuals with OUD face elevated risks due to this potent drug supply, which has increased the prevalence of opioid toxicity and complicated treatment retention. Methadone and other opioid agonist treatments (OATs) remain effective options, but their success depends on achieving therapeutic doses that address withdrawal and cravings. The observed trends in methadone prescribing practices, particularly the adoption of higher doses and combination therapy, are steps towards meeting these challenges, but the lack of rapid dose increases indicates room for improvement.

Future Directions for Methadone Prescribing Practices

To enhance the effectiveness of methadone treatment, further research is needed to evaluate the safety and efficacy of higher-dose regimens and combination therapies. Understanding the reasons behind limited dose titration—whether due to prescriber hesitancy, lack of evidence, or systemic barriers—will be critical to developing evidence-based protocols. Additionally, comparing methadone prescribing practices across regions, such as Ontario and British Columbia, where higher doses and faster titration are more common, can provide insights into best practices. Supporting prescribers with clear guidance and reducing logistical barriers, such as the need for frequent in-person assessments, could facilitate more rapid and effective dose adjustments, ultimately improving treatment outcomes.

Conclusion

Methadone treatment trends in Ontario reflect a dynamic response to the opioid crisis, with higher starting doses and the integration of SROM marking significant progress. However, the limited provision of rapid dose titration remains a critical gap, potentially hindering the ability to meet the needs of individuals with high opioid tolerance. By addressing these challenges and continuing to refine methadone prescribing practices, healthcare providers can better support individuals in their recovery journey, reducing reliance on unregulated drugs and improving long-term outcomes in the face of an evolving opioid crisis.

Source: JAMA Network